ASCO 2024: Updates in the Treatment of Advanced EGFR-Mutant NSCLC

Following the 2024 ASCO Annual Meeting, medical oncologists share insights on how the availability of the FLAURA2 treatment regimen has impacted the treatment of patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC).

Martin Dietrich, MD, PhD, discusses the secondary analysis from MARIPOSA evaluating first-line amivantamab plus lazertinib in patients with advanced EGFR-mutant NSCLC.

Wade T. Iams, MD, outlines insights gleaned from recently presented data from the PALOMA-3 trial in advanced EGFR-mutant non–small cell lung cancer.

Focusing on treatment practices for patients with advanced EGFR-mutant NSCLC, Martin Dietrich, MD, PhD, discusses how the availability of subcutaneous amivantamab can potentially address current treatment barriers.

Wade T. Iams, MD, provides clinical insights on proactive management strategies for patients receiving amivantamab for advanced EGFR-mutant NSCLC.

Martin Dietrich, MD, PhD, shares expert perspectives on recent data from TROPION-Lung05 and HERTHENA-Lung01 in advanced EGFR-mutant NSCLC.

Medical oncologists discuss the overall research landscape in advanced EGFR-mutant NSCLC, highlighting exciting trials and emerging data in the evolving treatment space.